PTJ
CYTK icon

Paul Tudor Jones’s Cytokinetics CYTK Stock Holding History

Paul Tudor Jones’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Buy
132,400
+125,200
+1,739% +$8.99M 0.02% 760
2026
Q1 		$475K Buy
7,200
+2,600
+57% +$165K ﹤0.01% 2856
2025
Q4 		$292K Sell
4,600
-100
-2% -$6.22K ﹤0.01% 3070
2025
Q3 		$258K Buy
+4,700
New +$194K ﹤0.01% 3070
2024
Q2 		– Sell
-9,700
Closed -$680K – 2397
2024
Q1 		$680K Buy
+9,700
New +$750K ﹤0.01% 1512

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's CYTK Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Cytokinetics (CYTK) in Q2 2026: 92,680 shares worth $7.9M. The stake represents 0.01% of the portfolio and ranks #967 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in CYTK as recently as Q2 2024.

Paul Tudor Jones first reported a position in CYTK in Q2 2014 and has held it in 22 quarters since. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Paul Tudor Jones held 92,680 shares of Cytokinetics worth $7.9M as of Q2 2026.
  • Cytokinetics was a new Paul Tudor Jones position in Q2 2026.
  • Cytokinetics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #967 holding.
  • Paul Tudor Jones first reported a position in Cytokinetics in Q2 2014 and has held it in 22 quarters since.
  • 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.